Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

New 11beta-HSD1 inhibitors described in recent Merck patent

Feb. 9, 2005

Improved outcome found with rosiglitazone in diabetic patients with cardiovascular disease

Feb. 9, 2005

Ligand earns milestone for initiation of phase II for SB-497115

Feb. 9, 2005

Preclinical data published on NBI-42902, a GnRH receptor antagonist

Feb. 9, 2005

BMS claims calcium-sensing receptor antagonists with utility in bone disorders

Feb. 8, 2005

Pfizer submits lasofoxifene sNDA for treatment of vaginal atrophy

Feb. 8, 2005

Preliminary phase IIb results on the effects of oral insulin spray in type 1 diabetes

Feb. 8, 2005

HMG-CoA reductase inhibitors identified by Ranbaxy team

Feb. 4, 2005

NovoLog Mix 70/30 reported effective as initiating insulin therapy for type 2 diabetes

Feb. 4, 2005

GTx initiates phase I trial for ostarine

Feb. 4, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...